Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
Treatment of castration-resistant prostate cancer remains an area of unmet medical need. Evidence suggests that this entity continues to be driven by androgens and androgen receptor (AR) signaling. Abiraterone acetate, a pregnenolone derivative, is an oral selective and irreversible inhibitor of the...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904375/ |